ClinicalTrials.gg
Active, not recruitingNCT04555174BIOFLOW-VIIIUpdated Jun 21, 2024

BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry

An observational study in Coronary Artery Disease and Myocardial Ischemia, sponsored by Biotronik AG. Active, not recruiting at 41 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Biotronik AG (formerly part of Biotronik SE & Co. KG) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
872
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG — 1 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Biotronik SE & Co. KG.

Enrollment
8th of 20
872 · median 528
Started
2020
with 4 others
Observational
20 of 37
1 open now
Registered
35th of 37
by date

Among the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG, this one is the 8th largest by enrollment of the 20 observational ones that give a count, is one of 5 that started in 2020, is one of 20 observational ones, and was the 35th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Coronary Artery Disease by Biotronik SE & Co. KG, or all of them as a file.
02

Study summary

The BIOFLOW-VIII registry is a post-market clinical evaluation of the Orsiro Mission stent in subjects requiring coronary revascularization with Drug Eluting Stents (DES).

Read the detailed description

BIOFLOW-VIII is a national, prospective, non-randomized, multi-center, open-label registry to confirm both, the acute performance as well as the mid- and long-term safety and clinical performance of the Orsiro Mission stent in an all-comers patient population within daily clinical practice.

A total of 868 subjects will be enrolled at approximately 50 study sites in France. Clinical follow-ups will take place at 6, 12, 36 and 60 months post index-procedure. Follow-ups can be conducted by telephone.

A subgroup analysis will evaluate the outcomes for patients treated ambulatory with same day discharge.

03

Conditions studied

  • Coronary Artery Disease
  • Myocardial Ischemia

Keywords

  • Observational registry
  • All-comers open-label registry
  • Percutaneous Coronary Intervention (PCI)
  • Coronary revascularization
  • Orsiro Mission Drug Eluting Stent (DES)
  • Stenting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Orsiro Mission is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de-novo stenotic lesions and in-stent restenotic lesions (length ≤ 40 mm) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic coronary artery disease intended to be treated with an Orsiro Mission DES (silent ischemia is permitted)
  • Subject has signed for data release
  • Subject is geographically stable and willing to participate at all follow up assessments
  • Subject is ≥ 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Subject did not sign for data release
  • Pregnancy
  • Known allergy (which cannot be pre-treated) to all types of P2Y12 inhibitor (Clopidogrel, Ticagrelor, Prasugrel, Ticlopidine and Cangrelor; thus preventing the use of the appropriate P2Y12 inhibitor), aspirin, both heparin and bivalirudin, L-605 cobalt- chromium (Co-Cr) alloy or one of its major elements (cobalt, chromium, tungsten, nickel), silicon carbide, PLLA, mTOR inhibiting drugs such as sirolimus, or contrast media
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
872 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Orsiro Mission DES

    All subjects will be implanted with the Limus Eluting Orsiro Mission Stent System and followed up until 60 months.

    Device: Orsiro Mission DES

Interventions

  • DeviceOrsiro Mission DES

    Percutaneous Coronary Intervention (PCI)

06

What researchers measure

Primary outcomes

  1. Rate of Target Lesion Failure (TLF) at 12 months follow-up

    TLF according to Academic Research Consortium-2 (ARC-2) definition: Composite of Cardiovascular Death, target-vessel Myocardial Infarction and clinically-driven Target Lesion Revascularization

    Time frame: 12 months

Secondary outcomes

  1. Rate of Target Lesion Failure (TLF) at 6, 36 and 60 months follow-up

    Time frame: 6, 36, and 60 months

  2. Rate of Target Vessel Revascularization (TVR) at 6, 12, 36, and 60 months follow-up

    Time frame: 6, 12, 36, and 60 months

  3. Rate of Target Lesion Revascularization (TLR) at 6, 12, 36, and 60 months follow-up

    Time frame: 6, 12, 36, and 60 months

  4. Rate of Definite Stent Thrombosis at 6, 12, 36, and 60 months follow-up

    Time frame: 6, 12, 36, and 60 months

  5. Percent of participants with Clinical Device Success defined as attainment of < 30% residual stenosis of the target lesion using Orsiro Mission only

    Time frame: Immediately after the intervention/procedure/surgery

  6. Percent of participants with Clinical Procedural Success defined as attainment of < 30% residual stenosis of the target lesion using any percutaneous method without occurrence of in-hospital death, myocardial infarction or target lesion revascularization

    Time frame: From the intervention/procedure/surgery until hospital discharge, assessed up to 3 days

07

Study locations

41 sites
08

References and documents

Individual participant data

Plan to share: No — The primary outcome data will be shared after publication of it.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jan 2023, 27 months.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's 27 months is close to that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2020
First posted
Sep 18, 2020
StartActual
Sep 25, 2020
Primary completionActual
Jan 18, 2023
CompletionEst.
Feb 19, 2027
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04555174
Lead sponsor
Biotronik AG
Collaborators
Biotronik France
Responsible party
Sponsor
First posted
Sep 18, 2020
Start date
Sep 25, 2020
Primary completion
Jan 18, 2023
Completion
Feb 19, 2027 (estimated)
Last update
Jun 21, 2024

Study contacts

Paul Barragan, MD
principal investigator · Polyclinique les Fleurs

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion